Meeting
2019 ASCO Annual Meeting
First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.
Authors
Debbie Robbrecht
Erasmus MC, Rotterdam, Netherlands
Debbie Robbrecht , Ferry Eskens , Emiliano Calvo , Xiaomin He , Hiroshi Hirai , Nital Soni , Natalie Cook , Afshin Dowlati , Angelica Fasolo , Victor Moreno , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Conduct of Clinical Research
Clinical Trial Registration Number
NCT02448589
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3063)
DOI
10.1200/JCO.2019.37.15_suppl.3063
Abstract #
3063
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2017 ASCO Annual Meeting
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
First Author: Kian-Huat Lim
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
First Author: Liza C Villaruz